US 10,369,230 B2 · Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy

Abstract

A nanoparticle that has a membrane including a polylactide-block-poly(ethylene glycol)-block-polylactide (PLA-PEG-PLA) and a polyvinyl alcohol, a bovine serum albumin contacting the membrane on the outside of the nanoparticle, a targeting group attached to the outside of the nanoparticle, and a breast cancer therapeutic agent that is encapsulated by the membrane. A nanoparticle that consists of a membrane including a polylactide-block-poly(ethylene glycol)-block-polylactide (PLA-PEG-PLA) and a polyvinyl alcohol, a bovine serum albumin contacting the membrane on the outside of the nanoparticle, breast cancer therapeutic agent that is encapsulated by the membrane, and an anti-Her2 antibody attached to the outer surface of the nanoparticle. A range of a number average molecular weight of the PEG block is 800 Da to 3 kDa and a range of a number average molecular weight of each of the PLA blocks is from 1 kDa to 5 kDa.

Claims20

Dependent claims

A nanoparticle having an interior space and a membrane surrounding the interior space,

wherein the interior space contains letrozole that is encapsulated by the membrane, and the membrane comprises;
a polylactide-block-poly(ethylene glycol)-block-polylactide block (PLA-PEG-PLA) copolymer wherein a number average molecular weight range of the PEG block is 800 Da to 3 kDa and a number average molecular weight range of each of the PLA block is from 1 kDa to 5 kDa,
a polyvinyl alcohol polymer,
bovine serum albumin in contact with the outer surface of the membrane, and
anti-Her2 antibody attached to the outer surface of the membrane.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/480,817Filed 6 Apr 2017

Published

US 2018/0289837 A111 Oct 2018

Granted

6 Aug 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 47/6935
The material constituting the nanoparticle being a polymer: the polymer being obtained otherwise than by reactions involving carbon to carbon…
A61K 31/4196
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: 1,2,4-Triazoles
A61K 47/68
The non-active ingredient being a modifying agent: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/6937
The polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol:…

Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy

Life of this patent

Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy

Life of this patent

Abstract

Claims20